Safety and Pharmacokinetics of Exebacase in an Infant with Disseminated Staphylococcus aureus Infection.
Journal Article (Journal Article)
Exebacase, an anti-staphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics (PK). Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.
Full Text
Duke Authors
- Cohen-Wolkowiez, Michael
- Fowler Jr., Vance Garrison
- Greenberg, Rachel Gottron
- Hornik, Chi
- Kumar, Karan Ravindra
Cited Authors
- Moorthy, GS; Greenberg, RG; Hornik, CD; Cassino, C; Ghahramani, P; Kumar, KR; Fowler, VG; Cohen-Wolkowiez, M
Published Date
- December 11, 2021
Published In
- Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
PubMed ID
- 34894129
Electronic International Standard Serial Number (EISSN)
- 1537-6591
Digital Object Identifier (DOI)
- 10.1093/cid/ciab1015
Language
- eng
Conference Location
- United States